SCHEMBL5155501

SCHEMBL5155501

CCSc1ccc(C2SCC(=O)N2CC(Cc2ccccc2)C2=COCO2)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
POLB P06746 1/20 0.41
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 5/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
GAA P10253 2/20 0.39
ATM Q13315 1/20 0.39
LMNA P02545 5/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PSMD14 O00487 1/20 0.37
GPR55 Q9Y2T6 1/20 0.37
ALOX12 P18054 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5149508 0.91 MEN1 (0.44) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL5151419 0.82 KMT2A (0.46) MEN1KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL5151385 0.79 KMT2A (0.38) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL5155154 0.79 ALDH1A1 (0.42) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL5156971 0.79 KMT2A (0.37) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL5152312 0.79 HCRTR1 (0.46) MEN1KMT2AALDH1A1
SCHEMBL5152138 0.76 KMT2A (0.41) MEN1KMT2APOLBALDH1A1SMN1; SMN2
SCHEMBL5151511 0.76 KMT2A (0.33) MEN1KMT2APOLBALDH1A1HPGD
SCHEMBL5156718 0.75 MEN1 (0.43) MEN1KMT2APOLBALDH1A1KDM4E
SCHEMBL5156370 0.73 CACNA1B (0.38) MEN1KMT2APOLBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7223754-B2 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-05-29 US disclosed
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2007-03-22 US disclosed
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-07-07 US disclosed
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders DYNOGEN PHARMACEUTICALS, INC. (US) 2005-05-26 US disclosed
WO-2004017965-A1 1,3-THIAZOLIN-4-ONES AS THERAPEUTIC COMPOUNDS IN THE TREATMENT OF PAIN IONIX PHARMACEUTICALS LIMITED (GB) 2004-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113421-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating non-inflammatory gastrointestinal tract disorders TRPV2, RYR2, VDAC2 MEN1 3532/4885KMT2A 4084/4885POLB 4811/4885
US-20070066597-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MEN1 3820/4885KMT2A 3401/4885POLB 4735/4885
US-20050148587-A1 Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders RYR2, CACNB2, CACNA1I MEN1 3820/4885KMT2A 3401/4885POLB 4735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.